Form 4: PDS Biotechnology Grants Stock Options to Chief Medical Officer

PDS Biotechnology Corp's Chief Medical Officer, Kirk V. Shepard, was granted 150,000 employee stock options with an exercise price of $1.79, vesting over four years.

Summary

• Kirk V. Shepard, Chief Medical Officer of PDS Biotechnology Corp (PDSB), was granted 150,000 employee stock options.
• The options have an exercise price of $1.79 per share.
• The transaction date for the option grant was June 12, 2025.
• The options will vest over four years, with 25% becoming exercisable on June 12, 2026.
• The remaining 75% will vest in 36 equal monthly installments after the initial vesting date, contingent on continued service.
• The expiration date for these options is June 12, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the stock option grant serves as an incentive for a key executive, aligning their long-term interests with the company's performance. It is a routine compensation event.

Positives

• The stock option grant serves as an incentive for the Chief Medical Officer, aligning his interests with shareholder value creation.
• It is a form of compensation that can help retain key executive talent.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders.

Future Outlook

The options are structured to vest over a four-year period, with the initial 25% vesting in June 2026 and the remainder vesting monthly thereafter, contingent on the Chief Medical Officer's continued service to the company.

Related Party Transactions

• Grant of 150,000 employee stock options to Kirk V. Shepard, the Chief Medical Officer, who is a related party.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from incentivized management performance.
• Employees (specifically the Chief Medical Officer): Receives a significant equity-based compensation package, providing a long-term incentive.

Next Steps

• The vesting of 25% of the options on June 12, 2026.
• Subsequent monthly vesting of the remaining 75% of options over 36 months, subject to continued employment.

Key Dates

Keywords

PDS Biotechnology, PDSB, Stock Options, Employee Stock Option, Chief Medical Officer, Executive Compensation, SEC Form 4, Insider Transaction, Vesting Schedule